CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Prostate Biopsy Specimen Analysis — Coverage Criteria

Defines coverage criteria and limitations for pathological examination of prostate biopsy specimens, including initial and repeat biopsies, and exclusion of saturation biopsy; applies to members of BlueCross BlueShield of Tennessee.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit pathology claims for prostate needle biopsy only for initial or follow-up non-saturation biopsies (extended ~12-core); saturation biopsy specimen analysis does not meet coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12-corerecommended extended sampling for initial diagnostic biopsy

saturationdefined as extensive sampling and does not meet coverage criteria

one vial/sextantspecimen handling note (≤2 cores per vial)

88305listed pathology procedure code

G0416listed prostate needle biopsy pathology code

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Prostate Biopsy Pathology

inv-01: Medically necessary indications — Covered when the following conditions are met

Covered when the following conditions are met:

Initial diagnostic biopsy: Pathological examination of tissue obtained from a prostate biopsy involving 12‑core extended sampling meets coverage criteria for initial diagnosis following abnormal PSA, a palpable nodule on digital rectal examination, or suspicious radiologic findings.12 cores

See specimen handling Note 1.

Repeat biopsy after negative initial biopsy: Pathological examination of tissue from a follow‑up prostate biopsy (excluding prostate saturation biopsy) meets coverage criteria when clinical suspicion for prostate cancer persists after a negative initial biopsy.exclude saturation

Saturation biopsy is excluded from coverage.

inv-02: Not medically necessary / Exclusion

Not covered: Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria for the diagnosis, staging, or management of prostate cancer.saturation biopsy (extensive sampling up to 24+ cores)

Lack of sufficient evidence of benefit and higher complication rates.

inv-03: Preferred biopsy techniques and surveillance timing — Preferred approaches and timing referenced by clinical guidelines

Preferred approaches and timing referenced by clinical guidelines:

Initial and repeat biopsy approach: When pre‑biopsy multiparametric MRI is available, combine MRI‑targeted biopsy with systematic sampling using an extended pattern of at least 12 cores for initial biopsy; targeted techniques include cognitive targeting, TRUS‑MRI fusion, and in‑bore MRI guidance.

NCCN and ACR recommend combined targeted and systematic approaches when MRI‑targeting capabilities are available.

Repeat biopsy considerations: Repeat prostate biopsy and/or repeat multiparametric MRI may be considered for active surveillance or persistent clinical suspicion but generally should not be performed more often than every 12 months unless clinically indicated (for example, rising PSA).12 months

NCCN guidance for active surveillance.

Transperineal versus transrectal: ESMO recommends transperineal biopsies rather than transrectal ultrasound‑guided biopsies, and advises performing targeted biopsy when multiparametric MRI is positive (PI‑RADS ≥3).

Pathological examination of tissue obtained from a prostate saturation biopsy is specifically excluded from coverage. The policy states that pathological examination of tissue obtained from a prostate saturation biopsy DOES NOT MEET COVERAGE CRITERIA for the diagnosis, staging, or management of prostate cancer due to lack of sufficient published evidence of benefit. This exclusion applies regardless of clinical setting and may result in denial of claims for pathology services on saturation biopsy specimens.

The NCCN recommends image-guided biopsy with targeting when pre-biopsy MRI identifies lesions and endorses an extended sampling pattern of at least 12 cores. The guideline notes that anteriorly directed biopsy is not supported in routine (initial) biopsy, but may be added to an extended biopsy protocol during a repeat biopsy if PSA remains persistently elevated.

This policy references major guideline and peer-reviewed sources to contextualize coverage decisions, including the NCCN Early Detection guidelines and ESMO clinical practice guidance, as well as AUA technical guidance and multiple primary studies and systematic reports on saturation, extended, fusion, and MRI-targeted biopsy techniques. Representative citations include the NCCN prostate detection guideline, ESMO Prostate Cancer Clinical Practice Guidelines (Parker et al., 2020), AUA consensus on prostate biopsy and specimen handling, and multiple comparative studies of biopsy strategies and outcomes.

Saturation biopsy specimen analysis is considered not medically necessary because available literature does not demonstrate that extensive sampling (commonly described as up to 20–24+ cores) provides sufficient additional clinical benefit to justify its routine use for diagnosis, staging, or management. The policy explicitly indicates the lack of published scientific literature confirming benefit as the rationale for excluding pathological examination of prostate saturation biopsy specimens from coverage.

Excerpts provided from referenced publications and bibliographies do not themselves include separate insurer-formatted statements labeled “Not Medically Necessary.” Instead, the policy text and its referenced evidence base are used to support the coverage determination; the absence of differently worded denial statements in the cited reference list does not change the policy’s explicit exclusion of saturation biopsy pathology as noted elsewhere in this document.

Coding and Procedure Codes

Maximum cores needed for csPCa detection in SPBx

Maximum cores for SPBx to detect clinically significant prostate cancer (csPCa)20 cores

Rationale from studyInitial 20 needle cores obtained from SPBx identified all 222 cases of csPCa in the referenced cohort

Effect on indolent cancersSPBx missed 84 of 129 indolent cases, reducing overdiagnosis of indolent disease

MRI positivity (PI-RADS) threshold

MRI positivity threshold (PI-RADS)PI-RADS ≥3

Action when mpMRI is positivePerform targeted (systematic or non-systematic) biopsy when mpMRI is PI-RADS ≥3

Provider Actions, Billing, and Documentation

Denial Risk

Coverage requirement

Pathological examination for initial diagnostic (12-core) and follow-up non-saturation prostate biopsies meet coverage criteria. Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria and may be denied.

Coverage: Initial 12-core extended sampling — covered
Coverage: Follow-up prostate biopsy (excluding saturation biopsy) — covered
Not covered: Pathology from prostate saturation biopsy — may be denied

Billing Rule

Pathology procedure codes

Procedure coding for pathology of prostate needle biopsy should be submitted using the listed CPT/HCPCS codes. Codes shown are for reference and may not be all-inclusive.

Background and Clinical Context

Prostate cancer spans a spectrum from indolent to aggressive disease. Indications for prostate biopsy include abnormal PSA values, a palpable nodule on digital rectal examination, or suspicious imaging findings. For initial diagnostic evaluation the policy supports an extended 12‑core systematic sampling approach, which has been validated to improve cancer detection compared with traditional sextant biopsy. When initial biopsy is negative but clinical suspicion persists, repeat biopsy (excluding saturation biopsy) is covered. The policy contrasts these recommended approaches with saturation biopsy—an extensive sampling strategy that acquires many more cores—which the policy does not support for routine diagnostic, staging, or management purposes.

Definitions and Abbreviations

mpMRI definition

DefinitionmpMRI = Multi-parametric magnetic resonance imaging

Acronym sourceTable of Terminology in policy document (ACR/ESMO/NCCN context)

Use in policyUsed as pre-biopsy imaging to guide targeted biopsy approaches when available

SBx definition

DefinitionSBx = Transrectal ultrasound biopsy

Typical applicationDescribes TRUS-guided systematic biopsy approach referenced in guidelines and comparisons

Abbreviation source

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit pathology claims for prostate needle biopsy only for initial or follow-up non-saturation biopsies (extended ~12-core); saturation biopsy specimen analysis does not meet coverage.

SourceLink

On This Page

ESMO notes higher detection of clinically significant cancer and fewer adverse events with transperineal targeted approaches.

Action when mpMRI is negativeWhen mpMRI is negative (PI-RADS ≤2) and clinical suspicion is low, biopsy can be omitted

Repeat biopsy frequency for active surveillance

Repeat biopsy frequency for active surveillanceNo more often than every 12 months unless clinically indicated (e.g., rising PSA)

ContextRepeat prostate biopsy and/or repeat multiparametric MRI may be considered for active surveillance or persistent clinical suspicion

Guideline sourceNCCN recommendation referenced for timing

Use CPT 88305 — Level IV surgical pathology, gross and microscopic examination
Use HCPCS G0416 — Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

Note

Conflict with government policy

If there is a conflict between this Policy and any applicable government policy (e.g., LCDs, NCDs, or state Medicaid), the government policy prevails. Refer to CMS and state Medicaid resources for the most current determinations.

Government policy (NCD/LCD/State Medicaid) overrides this Policy when conflicts exist
Medicare coverage search: https://www.cms.gov/medicarecoverage-database/search.aspx

Note

No explicit denial triggers are present

No explicit denial triggers are listed beyond the stated coverage limitations; references and guidance inform reimbursement and clinical expectations. Providers should ensure biopsy type and documentation align with coverage criteria to avoid claim denials.

No additional explicit denial triggers specified in this section
Ensure documentation supports that biopsy is initial 12-core or follow-up non-saturation to meet coverage

Documentation Required

Laboratory and specimen handling documentation

Laboratory-developed tests and specialized assays related to prostate biopsy specimens are regulated under CLIA as high-complexity tests. Laboratories must validate in-house tests and comply with CLIA requirements; FDA clearance is not required for LDT clinical use.

LDTs used for prostate biopsy analysis are regulated by CMS as high-complexity under CLIA '88
Labs must perform appropriate validation and comply with CLIA requirements
FDA clearance/approval is not currently required for clinical use of LDTs

Documentation Required

Specimen handling documentation

Follow specimen handling guidance to preserve diagnostic integrity: label and submit cores per recommended technique and limits.

One vial per sextant, with no more than two core samples per vial
Adhere to AUA Optimal Techniques of Prostate Biopsy and Specimen Handling guidance

Note

Imaging-guided pathway

Imaging-guided diagnostic pathways are supported: mpMRI prior to biopsy and MRI-targeted or fusion biopsy strategies improve detection of clinically significant cancer and are preferred when available.

Consider mpMRI before initial biopsy to triage need for biopsy and guide targeted sampling
Use MRI-targeted (fusion or in-bore) biopsy in conjunction with systematic sampling when MRI-targeting capabilities are available
Repeat systematic biopsy alone after multiple prior negatives has lower yield; combine with MRI-targeted biopsy

Note

Timing for repeat biopsy/MRI

For active surveillance, repeat biopsy and/or repeat mpMRI generally should not be performed more often than every 12 months unless clinically indicated (for example, rising PSA or rapid PSA doubling time). Follow guideline-specified triggers for earlier re-evaluation.

Repeat biopsy and/or mpMRI: generally no more often than every 12 months for active surveillance
Consider earlier MRI and repeat biopsy if PSA is rising or PSA doubling time < 3 years
Surveillance should include periodic DRE (at least yearly) and PSA (at least every 6 months)

Table of Terminology in policy document

TPM definition

DefinitionTPM = Template prostate mapping

Technique noteTemplate mapping is a systematic transperineal approach referenced among biopsy methods

Abbreviation sourceTable of Terminology in policy document

MRI positive (PI-RADS ≥3) definition as used by ESMO

ESMO/Policy definitionMRI positive defined as PI-RADS ≥3

Recommended actionPerform targeted (systematic or non-systematic) biopsy when mpMRI is PI-RADS ≥3 (ESMO)

Related guideline noteNCCN also supports targeted biopsy based on pre-biopsy MRI findings and combined targeted/systematic sampling when available

Terms: saturation biopsy / extended biopsy / fusion biopsy / MRI-targeted cores

Saturation biopsyExtensive sampling strategy (often up to 20–24+ cores) referenced in studies comparing detection rates

Extended biopsyAt least a 12-core systematic sampling pattern recommended/validated by guidelines (e.g., NCCN)

Fusion biopsy (FBx)MRI-TRUS fusion targeted biopsy technique shown to outperform 12-core systematic biopsy in certain repeat-biopsy settings

MRI-targeted coresCores obtained from lesions identified on mpMRI using cognitive targeting, fusion platforms, or in-bore MRI guidance; recommended to be combined with systematic sampling when possible